- Details
- Description
-
Packaging Size12Bottle/Box
-
Strength120mg(4ml)
-
CompositonZimberelimab
-
TreatmentClassical Hodgkin's lymphoma,Cervical cancer
-
Forminjection
-
Brand誉妥
-
Quantity Unit120mg(4ml)*12Bottle/Box
-
ManufacturerGloria Biosciences Co. Ltd., China
Zimberelimab is an anti-programmed cell death protein-1 (PD-1) monoclonal antibody being developed by Gloria Biosciences, Arcus Biosciences and Taiho Pharmaceutical Co. for the treatment of various cancers including cervical cancer, non-small cell lung cancer and classical Hodgkin's lymphoma. Based on the results of a phase II trial, zimberelimab was recently approved for marketing in China as treatment for relapsed or refractory classical Hodgkin's lymphoma.
- Zimberelimab sold under the brand name 誉妥® in china.
On July 4, 2023, Zimberelimab was approved by NMPA for the treatment of recurrent or metastatic cervical cancer with positive PD-L1 expression (CPS ≥ 1) that has progressed after one or more lines of standard platinum-containing chemotherapy.
